Leveraging Common Cross-Tissue Fibrotic Mechanisms to Validate Drug Candidates
Time: 12:30 pm
day: Conference Day One
Details:
- Identifying common fibrotic mechanisms across liver, lung and kidney fibrosis to enable a unified approach to anti-fibrotic discovery and accelerate drug development
- Using precision cut lung slices, multi omics to provide a highly physiologically relevant model enhances predictive accuracy of physiologically relevant models
- Leveraging reverse translation to ensure alignment between preclinical studies and human disease biology to increase likelihood of clinical success
